- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06655454
Supplerende postoperativ bupivakain etter ikke-kirurgisk endodontisk behandling
Effekten av supplerende postoperativ 0,5 % bupivakain med 1:200 000 epinefrin etter ikke-kirurgisk endodontisk behandling på pasienters livskvalitet, smerte og smertestillende forbruk
The study will investigate the impact of an additional injection of long-acting anesthetic on pain level, quality of life, and use of pain medication after a nonsurgical endodontic treatment. The long-acting anesthetic will be compared to a mock injection group and a group with no additional anesthetic to determine any differences in effects.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
The study will investigate the impact of postoperative supplemental long-acting bupivacaine on patient's pain, quality of life, and analgesic use following treatment for symptomatic irreversible pulpitis on patients with pre-operative pain levels of 5 or above (on a 0-10 analog scale). Bupivacaine will be compared to a placebo/mock injection and no injection to determine the difference in effect.
Studietype
Registrering (Antatt)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: Lorel E Burns, DDS
- Telefonnummer: 212-998-9332
- E-post: leb409@nyu.edu
Studer Kontakt Backup
- Navn: NYUSOM IRB
- Telefonnummer: 212-263-4110
- E-post: irb-info@nyulangone.org
Studiesteder
-
-
New York
-
New York, New York, Forente stater, 10010
- Rekruttering
- New York University College of Dentistry
-
Ta kontakt med:
- Lorel E Burns, DDS, MS
- Telefonnummer: 212-998-9332
- E-post: leb409@nyu.edu
-
Hovedetterforsker:
- Lorel E Burns, DDS
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Medical ASA Class I or II
- Patients above 18 years old
- Patients with a blood pressure below 160/100
- Patients who are treatment planned and have agreed to have emergency endodontic therapy or non-surgical root canal therapy with a pulpal diagnosis of symptomatic irreversible pulpitis according to the AAE Glossary of Endodontic Terms.
- Patients must be able to comprehend and complete all study protocols, written consent, and questionnaires in English.
Exclusion Criteria:
- Medical ASA III or above
- Patients who reported the use of tobacco or nicotine-containing products such as vapes, e-cigarettes, gums, or pouches and will not in the 48 hours following treatment
- Patients who reported the use of any marijuana products or illicit drugs in the 48 hours prior to treatment and will not in the next 48 hours.
- Patients who have taken opioids to control pain.
- Pregnant patients
- Patients with a blood pressure of 160/100 or greater
- Patients with a known hypersensitivity or allergy to any local anesthetic agent of the amide group, or any other components of the two anesthetic solutions such as epinephrine, sodium metabisulfite used in the study.
- Patients who have more than one tooth with odontogenic pain at the time of the screening.
- Patients who are unable to consent and do not understand or are unable to read the questionnaires.
- Patients who have had 4 1.7 ml carpules or more of anesthetic (Lidocaine and/ or Septocaine, 1:100,000) during standard care of treatment.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Støttende omsorg
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Supplemental Postoperative Bupivacaine
An additional injection, 1 carpule (1.8 mL) of 0.5% bupivacaine with 1:200,000 epinephrine, will be given to patients in this treatment arm, after their standard endodontic procedure is complete. |
This is the intervention of interest. A supplemental injection of bupivacaine will be given postoperatively to patients who are assigned this intervention. |
|
Placebo komparator: Mock/Placebo Injection
If assigned to this arm, the patient will be shown the removal of a needle cap for an anesthetic syringe. The tip will be bent and placed in the patient's mouth, but no tissue penetration will occur. No solution of anesthetic will be delivered. |
This intervention will appear to give patients an additional injection, but no additional drug will be given. |
|
Ingen inngripen: No Additional Injection
After standard endodontic procedure, no additional injection will be given. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Quality of life (scored based on the OHIP-14 questionnaire)
Tidsramme: Day of operation and daily for four days immediately following endodontic treatment
|
Quality of life will be measured with a modified version of the OHIP-14 questionnaire. For each question, the answers correspond with a scale that runs from 0-4. A higher score corresponds with a lower quality of life, with 0 being great quality of life and 4 being very poor quality of life. |
Day of operation and daily for four days immediately following endodontic treatment
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Postoperative pain level
Tidsramme: Day of operation and daily for four days immediately following endodontic treatment
|
Pain level as measured by the visual-analog scale (VAS) will be collected for four days following endodontic treatment. The scale is from 0-10, with 0 being no pain and 10 being the worst pain possible. |
Day of operation and daily for four days immediately following endodontic treatment
|
|
Analgesic use
Tidsramme: Day of operation and daily for four days immediately following endodontic treatment
|
Use of self-administered analgesics including opioids will be measured postoperatively. The measure is binary- either usage of self-administered analgesics or no usage of self-administered analgesics. |
Day of operation and daily for four days immediately following endodontic treatment
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- i24-01018
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .